Great! Foreign media: clinical research in Chile shows that Kexing vaccine is sa

According to the website of the third edition times of Chile on March 17, researchers submitted the results of clinical studies on the quality, immunogenicity and safety of the vaccine. Since November last year, researchers at Catholic University have been conducting a phase III clinical study on keshing's new coronal vaccine, kleinfer.

The preliminary results of the study involving nearly 2300 volunteers were submitted to relevant departments on the afternoon of the 17th, including data on the quality, immunogenicity and safety of the vaccine, the report said.
Alexis kalilsis, director of the Institute of immunology and immunotherapy, who led the study, stressed that the study was very important because first-hand information on the safety and immune induction ability of the vaccine to the national population could only be obtained by conducting trials in the national population.
Participants will be followed up for a period of one year, during which antibodies and T lymphocytes will be measured, which constitute acquired immunity and help determine whether immune protection can be maintained for more than one year, the report said.
"If neutralizing antibodies and T lymphocytes are down, it may be necessary to get another vaccine," carelhis explained
Katia awalka, clinical director of the study, pointed out that in terms of vaccine safety, the incidence of adverse reactions among participants was very low, and the symptoms were very mild. The most common reaction was pain at the vaccination site for one or two days. Less than 5% of the patients had low fever, some had other mild discomfort, and no serious adverse events were recorded. Therefore, the vaccine "has high safety".
The study evaluated the immune response of some of the volunteers who received the vaccine or placebo, the report concluded. The results showed that 14 days after the first dose, the antibody against S protein of NCV was increased in only a part of the inoculants, but two weeks after the second dose, the antibody was observed in 90% of the inoculants. It was also observed that these antibodies present after the second dose have neutralizing ability, that is, they will prevent the virus from entering human cells.